Curevo Vaccine Raises $110M in Series B for Shingles Vaccine

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110M in a Series B round. The fresh cash will help Curevo advance Phase 2 trials of amezosvatein, its shingles vaccine built from a non-living component of the virus and a proprietary adjuvant, a substance added to a shot to boost vaccine effectiveness. Shingles is a painful condition caused by reactivation of the virus that causes chicken pox.